Polaris Group (北極星藥業集團) yesterday said that phase 3 clinical trials for its mesothelioma treatment ADI-PEG 20 has been successful, adding that it plans to apply next year for marketing approval with the US Food and Drug Administration (FDA).
The trials showed that two main test gauges reached statistical significance, Polaris said, referring to overall survival (OS) — the time a patient survives from the beginning of treatment — and progression-free survival (PFS) time — the time a patient’s cancer does not worsen from the beginning of treatment.
The median OS time for the 125 participants treated with ADI-PEG 20 was 9.3 months, 21.4 percent higher than 7.66 months for the 124 participants in the control group, Polaris said.
Photo: CNA
The median PFS time was 6.11 months, compared with 5.59 months for the control group, it said.
The trials showed that 98.4 percent and 8.8 percent of all participants in the test group reported adverse events and serious adverse effects respectively, lower than 99.2 percent and 9.7 percent in the control group, it added.
“The small difference between the ratios of people with adverse effects in the two groups signifies the safety of ADI-PEG 20,” it said.
The trials were conducted in 38 hospitals in five countries: Taiwan, the US, the UK, Australia and Italy, it said.
As Polaris in February received the FDA’s fast-track designation, its application for marketing approval would be expedited, Polaris chairman Howard Chen (陳鴻文) told a news conference, adding that the company plans to submit the application at the beginning of next year.
Even though the number of people with mesothelioma is not high, totaling 38,000, the company is confident about the drug’s sales prospects, Chen said.
As Polaris developed ADI-PEG 20 with a metabolism-based strategy that depletes arginine, which causes stress and cytotoxicity in tumors, it could continue to try combining ADI-PEG 20 with other chemotherapy drugs for treating other kinds of cancer, the company said.
Polaris said that cumulative revenue in the first eight months of this year plunged 40 percent year-on-year to NT$5.55 million (US$176,527).
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained